Transfer of Voluntis Shares to the Euronext Growth Paris Market Effective on February 17, 2021
- New ticker: ALVTX
- ISIN code unchanged: FR0004183960
Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN:
FR0004183960 - the "Company"), a leader in the field of digital
therapeutics, announces the transfer of the Voluntis shares to
Euronext Growth Paris. This transfer, which was announced on
October 28, 2020, will be effective as of the February 17, 2021
This transfer to Euronext Growth Paris is intended to enable
Voluntis to be listed on a market more appropriate to its size. It
will enable the Company to reduce its costs and simplify its
operations while continuing to benefit from the attractiveness of
the financial markets by approaching new types of investors.
The proposed transfer was approved by the Company's shareholders
at an Ordinary Shareholders' Meeting held on December 17, 2020 and
implemented by the Board of Directors on the same day. The shares
will be listed on the Euronext Growth Paris market under an
accelerated listing procedure for existing shares, without the
issuance of new shares.
As of 17 February 2021, the new ticker for Voluntis shares will
be ALVTX. The ISIN code will remain unchanged: FR0004183960. In
addition, Voluntis shares will continue to be eligible for PEAs and
In order to ensure transparency for its investors and
shareholders, the Company has chosen to maintain the application of
IFRS. The other possible consequences of the transfer are recalled
in the Company's press releases published on October 28, 2020 and
December 17, 2020.
The information document relating to the transfer of the listing
of Voluntis shares on the Euronext Growth Paris market is available
on the following page of the Company's website
https://www.voluntis.com/fr/investors, in the Documents tab,
Regulated Information section, as well as on the Euronext website
as of today.
- The final schedule for the transfer of
the listing market is as follows:
February 11, 2021
- Notification by Euronext of the decision to list the shares on
Euronext Growth Paris.
February 15, 2021
- Distribution of a Euronext notice announcing the delisting of
Voluntis shares from Euronext Paris.
- Distribution of a Euronext notice announcing the listing of
Voluntis shares on Euronext Growth Paris.
- Publication of a press release by the Company and posting of
the information document online.
February 17, 2021 before the
opening of the markets
- Delisting of Voluntis shares from Euronext Paris.
- Listing of Voluntis shares on Euronext Growth Paris.
Next meeting: publication of the 2020 annual results on
March 30, 2021, after the close of trading.
Voluntis creates digital therapeutics that empower people with
chronic conditions to self-manage their treatment every day, thus
improving real-world outcomes. Voluntis’ solutions, combining
mobile and web apps, use clinical algorithms to deliver
personalized recommendations to patients and their care teams. For
example, these recommendations are used to adjust treatment dosage,
manage side effects or monitor symptoms.
Leveraging its Theraxium technology platform, Voluntis has
designed and operates multiple digital therapeutics, especially in
oncology and diabetes. Voluntis has long-standing partnerships with
leading life science companies. Based in Cambridge, MA, and Paris,
France, Voluntis is a founding member of the Digital Therapeutics
For more information, please visit: www.voluntis.com
Mnemo : VTX - ISIN : FR0004183960
version on businesswire.com: https://www.businesswire.com/news/home/20210216006230/en/
ACTUS Media relations Vivien Ferran email@example.com +33
(0)1 53 67 36 34
ACTUS Investor relations Jérôme Fabreguettes-Leib
firstname.lastname@example.org +33 (0)1 53 67 36 78
Voluntis Chief Financial Officer Guillaume Floch
email@example.com +33 (0)1 41 38 39 20
Gráfico Histórico do Ativo
De Dez 2021 até Jan 2022
Gráfico Histórico do Ativo
De Jan 2021 até Jan 2022